Pharmaceutical giant Mylan’s first attempt to quell widespread public outcry over the skyrocketing price of the EpiPen has fallen flat with members of Congress.
On Thursday, Mylan announced it will expand a patient assistance program and offer up to $300 in discounts to people whose insurance plans do not fully cover the device — but did not change the price of the EpiPen, which retails at around $600. The price has increased more than 400 percent in recent years.
The move comes after several days of criticism from lawmakers from both parties and Democratic presidential candidate Hillary Clinton demanding Mylan lower the price or offer an explanation for the increase and, in some cases, calling for government investigations into the matter.
